INMED PHARMACEUTICALS INC. Increase (Decrease) in Inventories
INMED PHARMACEUTICALS INC. (INM) reported Increase (Decrease) in Inventories of $56.73 thousand for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $127.09K.
- INMED PHARMACEUTICALS INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$70.37K.
- INMED PHARMACEUTICALS INC. increase (decrease) in inventories for the quarter ending 2025-06-30 was $147.20K, a 58.66% increase year-over-year.
- INMED PHARMACEUTICALS INC. increase (decrease) in inventories for the quarter ending 2025-03-31 was -$289.39K, a 164.44% decline year-over-year.
- INMED PHARMACEUTICALS INC. increase (decrease) in inventories for fiscal 2023 was -$565.56K, a 128.23% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. increase (decrease) in inventories for fiscal 2022 was $2.00M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2025-12-31 | $127.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $56.73K 10-Q · filed 2026-02-11 | $203.93K derived: sum of 3 quarters · filed 2026-07-02 | -$85.46K derived: sum of 4 quarters · filed 2026-07-02 |
| 2025-09-30 | -$70.37K 10-Q · filed 2025-11-06 | $76.84K derived: sum of 2 quarters · filed 2026-07-02 | -$212.55K derived: sum of 3 quarters · filed 2026-07-02 | -$329.27K derived: sum of 4 quarters · filed 2026-07-02 |
| 2025-06-30 | $147.20K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | -$142.18K derived: sum of 2 quarters · filed 2026-07-02 | -$258.90K derived: sum of 3 quarters · filed 2026-07-02 | -$283.15K S-4 · filed 2026-07-02 |
| 2025-03-31 | -$289.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | -$406.10K derived: sum of 2 quarters · filed 2026-02-11 | -$430.35K 10-Q · filed 2025-05-12 | -$337.57K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-12-31 | -$116.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$140.97K 10-Q · filed 2026-02-11 | -$48.19K derived: sum of 3 quarters · filed 2026-07-02 | $400.93K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-09-30 | -$24.25K 10-Q · filed 2025-11-06 | $68.53K derived: sum of 2 quarters · filed 2026-07-02 | $517.64K derived: sum of 3 quarters · filed 2026-07-02 | $299.86K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-06-30 | $92.78K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $541.89K derived: sum of 2 quarters · filed 2026-07-02 | $324.11K derived: sum of 3 quarters · filed 2026-07-02 | -$66.22K S-4 · filed 2026-07-02 |
| 2024-03-31 | $449.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $231.33K derived: sum of 2 quarters · filed 2025-05-12 | -$159.00K 10-Q · filed 2025-05-12 | -$140.41K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$217.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | -$608.11K 10-Q · filed 2025-02-12 | -$589.52K derived: sum of 3 quarters · filed 2025-02-12 | -$873.10K derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | -$390.33K 10-Q · filed 2024-11-14 | -$371.74K derived: sum of 2 quarters · filed 2024-11-14 | -$655.31K derived: sum of 3 quarters · filed 2024-11-14 | -$820.33K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $18.59K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$264.99K derived: sum of 2 quarters · filed 2024-09-30 | -$430.00K derived: sum of 3 quarters · filed 2024-09-30 | -$565.56K 10-K · filed 2024-09-30 |
| 2023-03-31 | -$283.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$448.59K derived: sum of 2 quarters · filed 2024-02-13 | -$584.15K 10-Q · filed 2023-05-15 | $486.32K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-12-31 | -$165.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$300.58K 10-Q · filed 2024-02-13 | $769.90K derived: sum of 3 quarters · filed 2024-02-13 | $1.20M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$135.56K 10-Q · filed 2023-11-14 | $934.91K derived: sum of 2 quarters · filed 2023-11-14 | $1.37M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $1.50M derived: sum of 2 quarters · filed 2023-09-29 | $2.00M 10-K · filed 2023-09-29 | |
| 2022-03-31 | $431.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $933.26K 10-Q · filed 2023-05-15 | ||
| 2021-12-31 | $501.70K 10-Q · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |